Minimally Invasive Breakthrough Technology Relieves Symptoms Quickly
and Durably While Preserving Sexual Function
PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company focused on addressing unmet
needs in urology, today announced that the company’s UroLift®
System, a novel, minimally invasive technology for treating lower
urinary tract symptoms due to benign prostatic hyperplasia (BPH), has
appeared on the popular television program “The Doctors,” distributed
nationally by CBS.
Richard David, M.D. of Skyline Urology in Los Angeles, Calif.,
demonstrated the use of the UroLift System to treat a patient with BPH,
and Aaron Spitz, M.D. of Orange County Urology Associates, discussed the
UroLift procedure in
a segment that aired yesterday.
Men who suffer from BPH often need to get up several times a night to
urinate, interrupting sleep and leading to fatigue and reduced quality
of life. Six months after his filmed UroLift treatment, the patient,
Jerry Budd of Lancaster, Calif., noted that he had woken in the night to
use the bathroom “maybe twice” since the procedure. The difference, he
said, has been “night and day,” with “absolutely zero” side effects.
Dr. Spitz explained that, unlike other procedures for BPH, the UroLift
procedure involves no destroying of prostate tissue, stating that the
evolution to a new gold standard in BPH treatment “is here now… because
the UroLift [System] actually has been demonstrated to have no sexual
side effects, and studies are now out to four years.”
The UroLift System permanent implants, delivered during a minimally
invasive procedure, act like window curtain tie-backs to hold the lobes
of an enlarged prostate open. The procedure takes less than one hour and
is typically performed using only local anesthetic in a physician’s
office or ambulatory surgery center, with no cutting, heating, or
removal of tissue. Patients recover from the procedure quickly,
returning to their normal routines with minimal downtime.
The UroLift System is a proven treatment that can get men off BPH
medications and allow them to avoid major surgery, while preserving
sexual function. Long-term clinical data from the LIFT randomized study
published in Urologic
Clinics of North America showed that, after four years, patients
treated with the UroLift device continue to experience symptom relief
with minimal side effects, with few patients requiring an additional
procedure for relief. A second randomized clinical trial called BPH6
demonstrated that the minimally invasive UroLift device compares very
well to the reference standard surgery, transurethral resection of the
prostate (TURP), with regard to efficacy, and is superior to TURP at
preserving sexual function and offering a more rapid recovery.2
More than 37 million men in the United States are affected by BPH. Not
to be confused with Prostate Cancer, BPH occurs when the prostate gland
that surrounds the male urethra becomes enlarged with advancing age and
begins to obstruct the urinary system. Symptoms of BPH often include
sleepless nights and urinary problems, and can cause loss of
productivity, depression and decreased quality of life.
Medication is often the first-line therapy for enlarged prostate, but
relief can be inadequate and temporary. Side effects of medication
treatment can include sexual dysfunction, dizziness and headaches,
prompting many patients to quit using the drugs. For these patients, the
classic alternative is surgery that cuts, heats or removes prostate
tissue to open the blocked urethra. While current surgical options can
be very effective in relieving symptoms, they can also leave patients
with permanent side effects such as urinary incontinence, erectile
dysfunction and retrograde ejaculation (dry orgasm).
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology
for treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during a
minimally invasive transurethral outpatient procedure, relieve prostate
obstruction and open the urethra directly without cutting, heating, or
removing prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged prostate
receiving UroLift implants reported rapid and durable symptomatic and
urinary flow rate improvement without compromising sexual function.
Patients also experienced a significant improvement in quality of life.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most symptoms
were mild to moderate in severity and resolved within two to four weeks
after the procedure. The UroLift System is available in the U.S.,
Europe, Australia and Canada. Learn more at www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company’s initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.NeoTract.com.
1 Roehrborn Urology Clinics 2016
2 Sonksen et al J Urology 2016
for NeoTract, Inc.
Nicole Osmer, 650-454-0505